Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Spf9.0
Sunscreen (SPF) – Forschung
Überwiegend Mechanismus / Beobachtung
8 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Sunscreen (SPF) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus mittelwertigen randomisierten Studien, veröffentlicht 1998–2024 mit einer typischen Studiengröße von 903 Teilnehmenden.
Basierend auf 8 Studien · 4 RCTs · 4,225 Teilnehmende insgesamt
Konfidenz
Mittlere Konfidenz
Nach Outcome
Skin healthDie am besten belegte Methode zur Vorbeugung von Falten und Lichtalterung — RCT-belegte 24 % geringere Progression der Hautalterung bei täglicher Anwendung (Prävention, keine Umkehr) · Fortlaufend (Prävention; über Jahre gemessen) · Beugt dem UV-bedingten Abbau von Kollagen/Elastin vor, der Erschlaffung und Verlust der Festigkeit verursacht · Fortlaufend
Überwiegend Mechanismus / Beobachtung5 Studien
Stetige Forschung
1 Studie in den letzten 5 Jahren
199820112024
1Systematische Übersicht2024
We present a review of oral photoprotectors and their effects.
Hartmann D, Valenzuela F. · Photodermatology, photoimmunology & photomedicine (2024)
Results Most of these effects of the sunlight are modulated by oxidative stress and proinflammatory mechanisms, therefore, the supplementation of substances that can regulate and neutralize reactive oxygen species would be beneficial for skin protection.
Current evidence indicates that systemic photoprotection should be used as an adjunctive measure to topical photoprotection.
Conclusion Oral photoprotectors are a promising option in improving protection against damage induced by UVR, as they contain active ingredients that increase the antioxidant effects of the body, complementing other photoprotection measures.
Skin aging from baseline to the end of the trial was 24% less in the daily sunscreen group than in the discretionary sunscreen group (relative odds, 0.76 [95% CI, 0.59 to 0.98]).
Hughes MC, Williams GM, Baker P, Green AC · Ann Intern Med (2013)
Randomized community trial (n=903): the daily sunscreen group showed no detectable increase in photoaging (skin microtopography) after 4.5 years
Daily use cut photoaging progression 24% vs discretionary use (relative odds 0.76, 95% CI 0.59-0.98)
Beta-carotene supplementation had no overall effect on skin aging; the landmark RCT for sunscreen as an anti-aging intervention
Ten years after trial cessation, 11 new primary melanomas had been identified in the daily sunscreen group, and 22 had been identified in the discretionary group
Green AC, Williams GM, Logan V, Strutton GM · J Clin Oncol (2011)
Long-term follow-up of the randomized Nambour sunscreen trial (1,621 adults) to 2006
Daily sunscreen roughly halved primary melanoma rate (HR 0.50, 95% CI 0.24-1.02) and substantially reduced invasive melanoma (HR 0.27)
Corroborates that UV damage is modifiable by routine sunscreen — cancer is a supporting endpoint here, not the photoaging outcome
the incidence of squamous-cell carcinoma was significantly lower in the sunscreen group than in the no daily sunscreen group (1115 vs 1832 per 100,000; 0.61 [0.46-0.81]).
Green A, Williams G, Neale R, et al. · Lancet (1999)
Original Nambour RCT (1,621 adults): 4.5 years of daily SPF 15+ sunscreen to head/neck/arms/hands
Daily sunscreen significantly reduced squamous-cell carcinoma incidence (rate ratio 0.61, 95% CI 0.46-0.81)
No harmful effect of daily use over the medium term — UV-driven cumulative skin damage is modifiable by routine sunscreen
all 6 of the tested active ingredients administered in 4 different sunscreen formulations were systemically absorbed and had plasma concentrations that surpassed the FDA threshold for potentially waiving some of the additional safety studies for sunscreens. These findings do not indicate that individuals should refrain from the use of sunscreen.
FDA randomized trial (n=48): chemical sunscreens applied under maximal-use conditions
All 6 active filters were systemically absorbed above the 0.5 ng/mL FDA threshold after a single day-1 application
The FDA explicitly states this does NOT mean people should stop using sunscreen — a safety-data gap, not evidence of harm (mineral filters are unaffected)
In the dermis and epidermis, AP-1 induces expression of matrix metalloproteinases collagenase, 92 kDa gelatinase, and stromelysin, which degrade collagen and other proteins that comprise the dermal extracellular matrix.
Mechanistic model: UV activates MAP-kinase pathways and AP-1, which upregulate matrix metalloproteinases (MMPs)
MMPs degrade dermal collagen; repeated UV causes imperfect repair that accumulates as visible photoaging
Establishes the biological rationale for why blocking UV (sunscreen) prevents collagen breakdown and photoaging
8Open-Labeln=32 · small study2016
The daily use of a facial broad-spectrum photostable sunscreen may visibly reverse the signs of existing photodamage, in addition to preventing additional sun damage.
Randhawa M, Wang S, Leyden JJ, Cula GO, Pagnoni A, Southall MD · Dermatol Surg (2016)
Single-arm prospective study (n=32): broad-spectrum SPF 30 applied daily to the face for 52 weeks
All photoaging parameters improved significantly vs baseline from week 12 through week 52 (texture/clarity/pigmentation 40-52%)
No control group and industry-sponsored — supports modest reversal but is weaker than a randomized design